Completed OBSERVATIONAL NCT00736242

Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)

Treatment of Chronic Hepatitis C in HIV-infected Patients With PegIntron Pen and Rebetol According to German Law (§ 67 Abs 6 AMG)

Sponsor: Merck Sharp & Dohme LLC

Conditions Chronic Hepatitis C HIV Infections Hepatitis C

Interventions PEG-IFN alfa-2b RBV

Updated 10 times since 2017 Last updated: Feb 2, 2015 Started: Dec 31, 2005 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Chronic Hepatitis C and HIV Infections and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 10 recorded versions since 2005 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2023 — Jul 2024 [monthly]

Completed
Dec 2022 — Jan 2023 [monthly]

Completed
Jun 2022 — Dec 2022 [monthly]

Completed

▶ Show 5 earlier versions

Jan 2021 — Jun 2022 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Feb 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.